Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions; Timolol; Travoprost

Criteria

Inclusion Criteria:

• ≥18 years;

• IOP=16-30mmHg

• OH or OAG with visual filed abnormality:

1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p <5% on the prepapillary diameter plot, one of which must have p <1%,

2. Glaucoma Hemifield Test outside normal limits,

3. Corrected Pattern Standard Deviation with p <5%

Exclusion Criteria:

• Previous damage of anterior chamber angle;

• ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) <1.0;

• contact lens wearer;

• severe central field loss;

• uncontrolled cardiovascular, hepatic or renal disease;

• any medication within past 1 month.